drugset
drugset / Trial / NCT06602258

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258 ↗

Phase 2 Active not recruiting 105 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

Timeline

Start
2024-09-30
Primary completion
2026-12-03
Completion
2027-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Etalanetug Monoclonal antibody — Intravenous
Background Lecanemab Monoclonal antibody — Subcutaneous

Indications

Alzheimer disease